Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Swiss drugmaker Sandoz is shifting gears from generics to biosimilars, unveiling its "Bio100" strategy at its capital markets day. The company aims to more than double net sales between 2025 and 2035, targeting mid-to-high single-digit annual growth through 2030. Biosimilars are set to become the majority of Sandoz's sales as it looks to expand its portfolio from 13 to 100 drugs by 2040.
Swiss drugmaker Sandoz is making a bold strategic pivot — away from generics and squarely toward biosimilars. At its capital markets day, the company unveiled its "Bio100" strategy, with the goal of growing its biosimilars portfolio from 13 drugs today to 100 by 2040. CEO Richard Saynor called it a defining shift, saying biosimilars are set to become the majority of the company's sales.
The financial ambitions are equally striking. Sandoz is targeting more than double its net sales between 2025 and 2035, with mid-to-high single-digit annual growth at constant currencies through 2030 — a step up from the mid-single-digit growth target it set at its 2023 capital markets day ahead of its spin-off from Novartis.
Why it matters: As biologics lose patent protection, biosimilars represent a massive and growing market opportunity. Sandoz's pivot signals a broader industry trend toward biosimilars as a key driver of pharmaceutical growth — and could have significant implications for drug pricing and patient access to complex therapies worldwide.
